StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
227
This month
2
This year
8
Publishing Date
2023 - 10 - 31
2
2023 - 10 - 18
2
2023 - 09 - 08
2
2023 - 08 - 08
2
2023 - 06 - 15
2
2023 - 05 - 09
2
2023 - 04 - 04
2
2022 - 12 - 16
4
2022 - 11 - 01
2
2022 - 09 - 16
2
2022 - 09 - 13
2
2022 - 07 - 26
2
2022 - 07 - 19
2
2022 - 04 - 18
2
2022 - 02 - 14
2
2022 - 01 - 04
2
2021 - 12 - 31
2
2021 - 11 - 26
2
2021 - 11 - 20
2
2021 - 11 - 17
2
2021 - 11 - 01
2
2021 - 09 - 23
2
2021 - 08 - 05
2
2021 - 06 - 17
2
2021 - 06 - 11
2
2021 - 06 - 10
1
2021 - 06 - 09
2
2021 - 06 - 07
1
2021 - 06 - 04
1
2021 - 05 - 27
1
2021 - 05 - 24
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 11
1
2021 - 05 - 10
1
2021 - 05 - 05
1
2021 - 05 - 03
1
2021 - 04 - 23
2
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 04 - 05
1
2021 - 03 - 15
1
2021 - 03 - 08
1
2021 - 03 - 01
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 02 - 18
1
2021 - 02 - 16
2
2021 - 02 - 04
3
2021 - 02 - 02
2
2021 - 01 - 28
1
2021 - 01 - 22
2
2021 - 01 - 15
1
2021 - 01 - 07
1
2021 - 01 - 06
1
2020 - 12 - 28
1
2020 - 12 - 21
1
2020 - 12 - 17
2
2020 - 12 - 09
1
Sector
Consumer durables
1
Consumer services
1
Distribution services
1
Electronic technology
1
Energy minerals
1
Finance
1
Health care and social assistance
1
Health technology
227
Manufacturing
2
N/a
2
Non-energy minerals
1
Process industries
2
Producer manufacturing
1
Retail trade
1
Technology services
3
Utilities
1
Tags
Agreement
2
Alliances
3
Antibody
3
Application
4
Approval
10
Approved
4
Australia
4
Authorization
24
Authorized
5
Awards
3
Biocapital
29
Biopharma
3
Bioscience
2
Biotech
2
Biotechnology
22
Canada
3
Candidate
2
Chmp
3
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
4
Conference
26
Congress
2
Covid
67
Covid-19
93
Deadline
5
Disease
7
Earnings
6
Emergency use authorization
10
Europe
9
Events
9
Fda
11
Financial
10
Financial results
7
Global
3
Grant
5
Granted
8
Grants
3
Health
7
India
10
Influenza
7
License
3
Merge
9
N/a
131
Nuvaxovid
3
Nvx-cov2373
5
Offering
6
People
4
Phase 2
5
Phase 2b
3
Phase 3
13
Positive
6
Product-news
3
Prototype
5
Research
10
Results
27
Submission
5
Switzerland
3
Trial
20
Vaccine
132
World
3
Entities
Abbott laboratories
1
Alector, inc.
1
Arcturus therapeutics holdings inc.
1
Ardelyx, inc.
1
Arrival
1
Astellas pharma inc
1
Astrazeneca plc
4
Baxter international inc.
1
Biogen inc.
2
Biontech se
3
Bristol-myers squibb company
1
Cidara therapeutics, inc.
1
Codexis, inc.
1
Emergent biosolutions, inc.
1
Endo international plc
1
Glaxosmithkline plc
4
Henry schein, inc.
1
Icosavax inc
1
Immunocellular therapeutics, ltd.
1
Inovio pharmaceuticals, inc.
1
Johnson & johnson
16
Legend biotech corporation
1
Lordstown motors corp.
1
Mks instruments, inc.
1
Moderna, inc.
9
Modivcare inc
1
Morgan stanley
1
Msci inc
1
Mueller industries, inc.
1
Netflix, inc.
1
Neurocrine biosciences, inc.
1
Newmont corporation
1
Nkarta, inc.
1
Novartis ag
1
Novavax, inc.
227
Nrg energy, inc.
1
Nutanix, inc.
1
Nutrien ltd.
1
Oge energy corp
1
Olympic steel, inc.
1
Omnicell, inc.
1
Ovintiv inc.
1
Par pacific holdings, inc.
1
Paycom software, inc.
1
Paypal holdings, inc.
1
Penumbra, inc.
1
Pfizer, inc.
2
Pinterest, inc.
1
Qualcomm incorporated
1
Rayonier advanced materials inc.
1
Regeneron pharmaceuticals, inc.
1
Relmada therapeutics, inc.
1
Renewable energy group, inc.
1
Renovacor, inc.
2
Sanofi
18
Snap inc.
1
Soligenix, inc.
1
Stoneco ltd.
1
Takeda pharmaceutical company limited
4
Walmart inc.
1
Symbols
AAPL
1192
ABB
1422
ABBV
1022
ABLZF
1161
ABT
1784
ACN
600
AMGN
741
ARVL
4284
AZN
664
BDX
796
BMY
662
BNPQF
1764
BNPQY
1764
CSCO
895
DHR
785
ERIC
1607
F
641
FNCTF
7170
FRBA
595
GE
915
GLAXF
657
GOOG
1271
GOOGL
1270
GSK
883
HON
1777
HUBS
1400
IBM
654
INTC
954
IT
590
JNJ
4571
LLY
1708
LTUM
970
LYV
717
MDT
1284
MMM
938
MS
4277
MSFT
1199
MT
588
NOC
588
NOK
898
NOKBF
972
NVO
631
NVS
1241
NVSEF
1031
ORCL
1156
PCRFF
650
PCRFY
650
PFE
692
PHG
962
PPRUF
1126
PPRUY
1127
SAP
1473
SAPGF
1227
SNOW
794
SNY
4532
SNYNF
3590
TEVJF
630
TMO
1621
VZ
1211
XYF
674
Exchanges
Nasdaq
227
Nyse
23
Crawled Date
2023 - 10 - 31
2
2023 - 10 - 18
2
2023 - 09 - 08
2
2023 - 08 - 08
2
2023 - 06 - 15
2
2023 - 05 - 09
2
2023 - 04 - 04
2
2022 - 12 - 16
4
2022 - 11 - 01
2
2022 - 09 - 16
2
2022 - 09 - 13
2
2022 - 07 - 26
2
2022 - 07 - 19
2
2022 - 04 - 18
2
2022 - 02 - 14
2
2022 - 02 - 11
2
2022 - 01 - 04
2
2021 - 12 - 31
2
2021 - 11 - 26
2
2021 - 11 - 17
2
2021 - 11 - 01
2
2021 - 09 - 23
2
2021 - 08 - 05
2
2021 - 06 - 11
2
2021 - 06 - 10
1
2021 - 06 - 09
2
2021 - 06 - 07
1
2021 - 06 - 05
1
2021 - 05 - 27
1
2021 - 05 - 24
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 11
1
2021 - 05 - 10
1
2021 - 05 - 06
1
2021 - 05 - 03
1
2021 - 04 - 24
1
2021 - 04 - 23
1
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 04 - 05
1
2021 - 03 - 15
1
2021 - 03 - 08
1
2021 - 03 - 01
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 02 - 18
1
2021 - 02 - 16
2
2021 - 02 - 04
3
2021 - 02 - 02
2
2021 - 01 - 28
1
2021 - 01 - 22
2
2021 - 01 - 15
1
2021 - 01 - 08
1
2021 - 01 - 06
1
2020 - 12 - 28
1
2020 - 12 - 21
1
2020 - 12 - 17
2
2020 - 12 - 09
1
Crawled Time
00:00
3
00:20
4
01:00
7
02:00
2
03:00
2
04:20
2
05:00
4
06:00
2
07:00
1
08:00
2
10:00
2
11:00
7
12:00
13
12:03
1
12:15
1
12:20
6
12:30
1
12:57
1
13:00
18
13:03
3
13:15
3
13:20
5
13:30
2
14:00
21
14:03
1
14:15
1
14:20
3
14:30
6
15:00
12
15:20
3
15:30
2
16:00
8
16:20
2
17:00
5
18:00
7
19:00
10
20:00
6
21:00
14
21:03
2
22:00
15
22:01
2
23:00
14
23:01
1
Source
www.biospace.com
96
www.fda.gov
1
www.globenewswire.com
20
www.prnewswire.com
110
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
NVAX
save search
Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom
Published:
2022-09-27
(Crawled : 13:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-78.86%
|
O:
4.56%
H:
9.68%
C:
1.57%
one
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
Published:
2022-09-16
(Crawled : 12:20)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.74%
|
O:
-2.61%
H:
2.24%
C:
-4.07%
covid-19
vaccine
israel
Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17
Published:
2022-09-16
(Crawled : 12:20)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.74%
|
O:
-2.61%
H:
2.24%
C:
-4.07%
covid-19
vaccine
authorization
FDA Roundup: September 13, 2022
Published:
2022-09-13
(Crawled : 19:00)
- fda.gov
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.04%
|
O:
1.2%
H:
5.65%
C:
4.49%
fda
Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older
Published:
2022-09-13
(Crawled : 15:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.91%
|
O:
-6.06%
H:
1.55%
C:
-0.71%
covid-19
vaccine
india
africa
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older
Published:
2022-09-12
(Crawled : 14:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.42%
|
O:
0.98%
H:
3.22%
C:
3.03%
covid-19
vaccine
granted
authorization
Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older
Published:
2022-09-02
(Crawled : 19:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.51%
|
O:
1.22%
H:
0.0%
C:
-6.03%
covid-19
vaccine
Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older
Published:
2022-09-01
(Crawled : 18:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-87.92%
|
O:
-0.51%
H:
0.19%
C:
-2.8%
covid-19
chmp
vaccine
authorization
Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight
Published:
2022-08-31
(Crawled : 16:00)
- prnewswire.com
SNYNF
|
$92.116
-2.18%
2.3K
|
Health Technology
|
15.64%
|
O:
0.75%
H:
1.98%
C:
1.98%
SNY
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
11.36%
|
O:
1.1%
H:
0.0%
C:
0.0%
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-88.67%
|
O:
1.39%
H:
1.34%
C:
-7.48%
MRNA
S
|
$103.45
-0.33%
-0.33%
2M
|
Health Technology
|
-23.64%
|
O:
0.75%
H:
2.14%
C:
-3.42%
CDTX
|
$0.73
0.0%
420K
|
Health Technology
|
4.93%
|
O:
1.15%
H:
0.0%
C:
-3.37%
companies
influenza
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17
Published:
2022-08-26
(Crawled : 14:20)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-89.29%
|
O:
-0.03%
H:
1.53%
C:
-5.48%
covid-19
vaccine
granted
authorization
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
Published:
2022-08-19
(Crawled : 23:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
covid-19
fda
grants
authorization
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
Published:
2022-08-18
(Crawled : 14:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-89.87%
|
O:
0.97%
H:
0.0%
C:
-6.47%
covid-19
vaccine
granted
approval
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
Published:
2022-08-17
(Crawled : 13:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-90.69%
|
O:
-1.82%
H:
1.31%
C:
-6.48%
covid-19
vaccine
granted
approval
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
Published:
2022-08-15
(Crawled : 13:20)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-90.38%
|
O:
2.44%
H:
1.6%
C:
-0.42%
covid-19
fda
application
authorization
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
Published:
2022-08-12
(Crawled : 14:00)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-90.11%
|
O:
2.03%
H:
4.62%
C:
0.75%
covid-19
vaccine
approved
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
Published:
2022-08-08
(Crawled : 22:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-93.38%
|
O:
0.91%
H:
3.17%
C:
-5.87%
results
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published:
2022-08-04
(Crawled : 13:20)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-93.47%
|
O:
0.31%
H:
3.16%
C:
1.03%
covid-19
global
children
vaccine
six
trial
phase 2b
Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022
Published:
2022-08-01
(Crawled : 21:00)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-92.68%
|
O:
-1.36%
H:
4.67%
C:
0.28%
conference
results
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
Published:
2022-07-26
(Crawled : 12:20)
- biospace.com/
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-92.81%
|
O:
-0.2%
H:
6.0%
C:
2.08%
covid-19
australia
vaccine
granted
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
Published:
2022-07-26
(Crawled : 12:20)
- prnewswire.com
NVAX
|
$3.895
-2.38%
-2.44%
3.7M
|
Health Technology
|
-92.81%
|
O:
-0.2%
H:
6.0%
C:
2.08%
covid-19
japan
vaccine
approval
← Previous
1
2
3
4
5
6
7
8
9
10
11
12
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.